- Home
- COLL vs RXST Comparison
COLL vs RXST Comparison
Compare COLL & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- RXST
- Stock Information
- Founded
- COLL 2002
- RXST 1997
- Country
- COLL United States
- RXST United States
- Employees
- COLL N/A
- RXST N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- COLL Health Care
- RXST Health Care
- Exchange
- COLL Nasdaq
- RXST Nasdaq
- Market Cap
- COLL 910.2M
- RXST 1.0B
- IPO Year
- COLL 2015
- RXST 2021
- Fundamental
- Price
- COLL $30.00
- RXST $26.12
- Analyst Decision
- COLL Strong Buy
- RXST Strong Buy
- Analyst Count
- COLL 5
- RXST 9
- Target Price
- COLL $43.60
- RXST $49.33
- AVG Volume (30 Days)
- COLL 444.8K
- RXST 564.7K
- Earning Date
- COLL 05-08-2025
- RXST 05-05-2025
- Dividend Yield
- COLL N/A
- RXST N/A
- EPS Growth
- COLL 43.56
- RXST N/A
- EPS
- COLL 1.86
- RXST N/A
- Revenue
- COLL $631,449,000.00
- RXST $139,927,000.00
- Revenue This Year
- COLL $20.00
- RXST $38.53
- Revenue Next Year
- COLL $3.93
- RXST $24.60
- P/E Ratio
- COLL $16.09
- RXST N/A
- Revenue Growth
- COLL 11.41
- RXST 57.09
- 52 Week Low
- COLL $27.28
- RXST $24.09
- 52 Week High
- COLL $42.29
- RXST $66.54
- Technical
- Relative Strength Index (RSI)
- COLL 51.96
- RXST 47.08
- Support Level
- COLL $29.01
- RXST $24.72
- Resistance Level
- COLL $30.53
- RXST $27.13
- Average True Range (ATR)
- COLL 0.89
- RXST 1.05
- MACD
- COLL 0.04
- RXST 0.32
- Stochastic Oscillator
- COLL 62.91
- RXST 66.78
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.